@article{a6125906c65e42eea94f74d166c1967b,
title = "Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 1.2020 featured updates to the NCCN guidelines",
abstract = "The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel{\textquoteright}s discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.",
author = "Daly, {Mary B.} and Robert Pilarski and Yurgelun, {Matthew B.} and Berry, {Michael P.} and Buys, {Saundra S.} and Patricia Dickson and Domchek, {Susan M.} and Ahmed Elkhanany and Susan Friedman and Garber, {Judy E.} and Michael Goggins and Hutton, {Mollie L.} and Seema Khan and Catherine Klein and Wendy Kohlmann and Kurian, {Allison W.} and Christine Laronga and Litton, {Jennifer K.} and Mak, {Julie S.} and Menendez, {Carolyn S.} and Merajver, {Sofia D.} and Norquist, {Barbara S.} and Kenneth Offit and Tuya Pal and Pederson, {Holly J.} and Gwen Reiser and Shannon, {Kristen Mahoney} and Kala Visvanathan and Weitzel, {Jeffrey N.} and Wick, {Myra J.} and Wisinski, {Kari B.} and Dwyer, {Mary A.} and Darlow, {Susan D.}",
note = "Funding Information: This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc. Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.",
year = "2020",
month = apr,
doi = "10.6004/jnccn.2020.0017",
language = "English (US)",
volume = "18",
pages = "380--391",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",
}